Department of Otolaryngology-Head and Neck Surgery and Maxillofacial Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Affiliated to the School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Eur Arch Otorhinolaryngol. 2024 Dec;281(12):6275-6281. doi: 10.1007/s00405-024-08839-y. Epub 2024 Jul 16.
To provide pooled analyses on the association between COVID-19 vaccine and the incidence of idiopathic sudden sensorineural hearing loss (ISSNHL).
"Medline" via "PubMed", "EMBASE", and "Google scholar".
Data sources were inspected from January 2020 to January 2024 using search terms relevant to vaccines for COVID-19. Included were papers with reported numbers of vaccinated populations and incidence if ISSNHL in those populations. Quality assessment was performed with the Newcastle-Ottawa Quality Assessment Scale Criteria.
Three publications encompassing more than 191.8 million patients and at least 283 million vaccine doses were included in the quantitative data synthesis. The pooled reported incidence (95%confidence interval) of ISSNHL among COVID-19 vaccine recipients was 1.2588 per 100,000 (0.1385-3.4836). This incidence is significantly lower than the incidence of 5-27 and 60 per 100,000/year reported in the United States and in the European Union, respectively (P < 0.0001).
There is no evidence to indicate that the COVID-19 vaccine is associated with the incidence of ISSNHL.
对 COVID-19 疫苗与特发性突发性聋（ISSNHL）发病率之间的关联进行汇总分析。
通过“PubMed”的“Medline”、“EMBASE”和“Google Scholar”检索了 2020 年 1 月至 2024 年 1 月与 COVID-19 疫苗相关的搜索词。纳入了报告接种人群数量和该人群中 ISSNHL 发病率的论文。使用纽卡斯尔-渥太华质量评估量表标准进行质量评估。
共有 3 篇文献纳入了超过 1.918 亿名患者和至少 2.83 亿剂疫苗的定量数据综合分析。COVID-19 疫苗接种者 ISSNHL 的报告发病率（95%置信区间）为每 100,000 人 1.2588 例（0.1385-3.4836）。这一发病率明显低于美国和欧盟分别报告的每年每 100,000 人 5-27 例和 60 例的发病率（P<0.0001）。
没有证据表明 COVID-19 疫苗与 ISSNHL 的发病率有关。
